Inavolisib
About
Therapy type: Targeted therapy
Therapy strategy: PI3K/AKT/mTOR inhibition
Mappings
NCI Thesaurus: Inavolisib (coding:ncit:C132166)
RxNorm: inavolisib (coding:rxcui:2695422, coding:omop:1735491)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| FDA (1) HC (1) | ER positive, HER2-negative, PIK3CA Somatic variants | Invasive Breast Carcinoma | Fulvestrant, Inavolisib, Palbociclib | |
| FDA (1) HC (1) | HER2-negative, PIK3CA Somatic variants, PR positive | Invasive Breast Carcinoma | Fulvestrant, Inavolisib, Palbociclib | |
| FDA (1) HC (1) | ER positive, HER2-negative, PIK3CA Somatic variants, PR positive | Invasive Breast Carcinoma | Fulvestrant, Inavolisib, Palbociclib |